Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PTIX
stocks logo

PTIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Protagenic Therapeutics Inc (PTIX.O) is -0.10, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Protagenic Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.72
Current PE
-0.10
Overvalued PE
2.49
Undervalued PE
-9.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PTIX News & Events

Events Timeline

(ET)
2025-11-13
08:44:17
Protagenic Therapeutics finishes enrollment and dosing for Phase 1 MAD study
select
2025-08-21 (ET)
2025-08-21
08:18:47
Protagenic progresses PT00114 to multiple-dose Phase 1 clinical trial
select
2025-07-30 (ET)
2025-07-30
08:33:13
Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-27SeekingAlpha
Protagenic Therapeutics issued a letter regarding Nasdaq non-compliance

  • Nasdaq Non-Compliance Notification: Protagenic Therapeutics (PTIX) received a notification from Nasdaq regarding its non-compliance with listing rules, specifically failing to meet the minimum stockholders' equity requirement of $2.5 million and not filing its September 30, 2025 Form 10-Q on time.

  • Delisting Determination: Due to recent compliance issues and a mandatory monitoring period, Nasdaq has determined to delist the company's securities, prompting PTIX to request a hearing to present its plan to rectify these deficiencies.

[object Object]
Preview
7.0
08-23SeekingAlpha
Protagenic Therapeutics Announces Timeline for Form 10-Q Filing and Nasdaq Compliance Update

  • Quarterly Report Filing Delay: Protagenic Therapeutics announced a delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025, due to merger-related financial statement consolidation.

  • Anticipated Brief Delay: The company expects the delay to be short, but cannot guarantee a specific timeline for the filing.

  • Nasdaq Notice Received: Protagenic confirmed it received a notice from Nasdaq regarding its failure to file the Quarterly Report, although this does not affect the trading of its securities.

  • Current Stock Performance: Following the announcement, Protagenic's stock price increased by 1.41% after hours, reaching $4.3.

[object Object]
Preview
9.0
08-22Benzinga
Protagenic Therapeutics (PTIX) Stock Rises Following Advancements in Clinical Trials

  • Stock Performance: Shares of Protagenic Therapeutics Inc (PTIX) surged over 100% after the announcement of a key clinical milestone in their Phase 1 trial for PT00114, a hormone therapy targeting stress and mood disorders.

  • Clinical Trial Update: The company successfully administered the first dose to all subjects in the multiple-dose portion of the trial and expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.

  • Therapeutic Approach: PT00114 is based on Teneurin C-terminus Associated Peptide, a naturally occurring brain hormone aimed at regulating stress and emotional balance, potentially offering a treatment with fewer side effects.

  • Current Stock Price: As of Thursday afternoon, PTIX shares were trading at $4.02, reflecting a 76% increase, with a notable 52-week high of $15.54 and a low of $2.25.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Protagenic Therapeutics Inc (PTIX) stock price today?

The current price of PTIX is 1.68 USD — it has decreased -6.93 % in the last trading day.

arrow icon

What is Protagenic Therapeutics Inc (PTIX)'s business?

Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.

arrow icon

What is the price predicton of PTIX Stock?

Wall Street analysts forecast PTIX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTIX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Protagenic Therapeutics Inc (PTIX)'s revenue for the last quarter?

Protagenic Therapeutics Inc revenue for the last quarter amounts to -1.11M USD, increased 70.82 % YoY.

arrow icon

What is Protagenic Therapeutics Inc (PTIX)'s earnings per share (EPS) for the last quarter?

Protagenic Therapeutics Inc. EPS for the last quarter amounts to -1167263.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Protagenic Therapeutics Inc (PTIX)'s fundamentals?

The market is revising No Change the revenue expectations for PTIX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -46.67%.
arrow icon

How many employees does Protagenic Therapeutics Inc (PTIX). have?

Protagenic Therapeutics Inc (PTIX) has 1 emplpoyees as of December 05 2025.

arrow icon

What is Protagenic Therapeutics Inc (PTIX) market cap?

Today PTIX has the market capitalization of 3.25M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free